Providing Veterans Essential Medications Act
- Sponsor
- Sen. King, Angus S., Jr. [I-ME]
- Committees
- Veterans' Affairs Committee (primary)
- Last action
- Sep 24, 2026
Bottom line
The bill aims to ensure veterans in State homes receive essential high-cost medications by having the VA cover these specific drug costs, thereby relieving State homes of a significant financial burden.
What it actually does
This bill directs the Department of Veterans Affairs (VA) to either reimburse State veterans' homes for the cost of certain high-cost medications provided to veterans receiving nursing home care, or to furnish these medications directly to the State homes. This new federal support is in addition to the existing payments the VA makes to State homes for veteran care. A 'costly medication' is defined as one whose monthly average wholesale price, plus a 3% transaction fee, exceeds 8.5% of the VA's monthly payment for the veteran's care.
Proponents argue
Supporters argue that this bill closes a critical gap in care for veterans residing in State homes, ensuring they have access to necessary, often life-saving, high-cost medications without placing an undue financial strain on State budgets or the State homes themselves. They contend it standardizes the quality of care for veterans, aligning medication access more closely with what veterans would receive in direct VA facilities and improving overall veteran well-being.
Opponents contend
Critics might express concerns about the potential for increased federal spending without a clear cap or detailed cost-benefit analysis, suggesting it could create a new unfunded mandate on the federal budget. They might also argue that the specific 8.5% threshold for 'costly medication' could be arbitrary, potentially shifting costs from states to the federal government for medications that states might otherwise be expected to cover, or that it could lead to administrative complexities for the VA.
The bill is very short and straightforward, making it highly accessible for a reader to understand its core provisions quickly.
Section 2
Reimbursement or Furnishing of Costly Medications to State Homes
This section amends existing law (title 38, United States Code, Section 1745(a)(3)) to require the VA to either pay State veterans' homes back for expensive medications or directly provide those medications to the homes. This is specifically for veterans receiving nursing home care in these State homes. The State home gets to choose whether they want reimbursement or direct furnishing. This new support is in addition to the regular payments the VA already makes for the veterans' care.
Supporters argue
Proponents argue this provision directly addresses a critical funding gap, ensuring that veterans receive necessary medications regardless of their care setting and preventing State homes from bearing unsustainable costs for these treatments. It promotes equitable care for all veterans.
Critics contend
Opponents might argue that this provision could lead to an uncapped increase in federal spending, as the definition of 'costly medication' could encompass a wide range of drugs, and the VA's budget would directly absorb these costs without clear limits. They may also point to potential administrative complexities for the VA in managing a new nationwide medication program for State homes.
Tradeoffs
The provision balances the goal of ensuring comprehensive veteran care with the potential for increased federal expenditure and administrative overhead. It shifts financial responsibility for high-cost medications from State homes to the federal VA, aiming to improve veteran access but potentially increasing the federal deficit.
Defines 'costly medication' as a drug or medicine for which the average wholesale price for one month's supply, plus a 3 percent transaction fee, exceeds 8.5 percent of the payment under subparagraph (A) by the Secretary to a covered State home for care provided to the veteran who receives such costly medication during such month.
Section 2, new subparagraph (C)(i)
Why it matters:The use of specific financial thresholds and calculations is standard legislative practice for defining eligibility criteria and cost parameters, rather than an attempt to obscure. However, the precise impact depends heavily on these details.
Case for: Supporters would argue that this specific definition provides a clear, objective standard for what constitutes a 'costly medication' that warrants federal intervention, preventing ambiguity and ensuring resources are directed to truly high-cost treatments.
Case against: Critics might contend that the 8.5% threshold is arbitrary and could either be too high, leaving some State homes burdened, or too low, leading to federal overspending on medications that states could reasonably cover. The 'average wholesale price' plus a '3 percent transaction fee' also introduces specific pricing mechanisms that could be debated.
Estimated impact: This definition directly determines which medications qualify for federal support, thus controlling the overall financial impact of the bill on the VA budget and the relief provided to State homes.